Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Receivables (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Change in Receivables for 16 consecutive years, with $212.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 8381.84% year-over-year to $212.0 million, compared with a TTM value of $266.5 million through Dec 2025, up 10560.52%, and an annual FY2025 reading of $57.0 million, changed N/A over the prior year.
  • Change in Receivables was $212.0 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $47.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $212.0 million in Q4 2025 and bottomed at -$68.2 million in Q2 2023.
  • Average Change in Receivables over 5 years is $16.3 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Change in Receivables tumbled 9960.0% in 2021, then surged 8381.84% in 2025.
  • Year by year, Change in Receivables stood at -$10.1 million in 2021, then skyrocketed by 477.61% to $38.2 million in 2022, then tumbled by 103.27% to -$1.2 million in 2023, then soared by 300.64% to $2.5 million in 2024, then soared by 8381.84% to $212.0 million in 2025.
  • Business Quant data shows Change in Receivables for ARWR at $212.0 million in Q4 2025, $47.1 million in Q3 2025, and $7.5 million in Q2 2025.